In cancers which are responsive to immune checkpoint inhibitors (ICI), the ICI treatment is predominantly more effective in male compared to female patients.88 As such, the efficacy of cGAS-STING agonists that are dependent on interferon stimulating genes (ISGs) particularly in MDCS with combinatory approaches like ICI might also be a function of sex in GBM. The gene discussed is STING1; the disease is glioblastoma.